Palisade Bio (NASDAQ:PALI) Raised to Strong-Buy at LADENBURG THALM/SH SH

Palisade Bio (NASDAQ:PALI) was upgraded by stock analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other analysts have also weighed in on the stock. Wall Street Zen lowered shares of Palisade Bio from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright began coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 target price for the company. Weiss Ratings lowered shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Stifel Nicolaus assumed coverage on Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock. Finally, Wolfe Research assumed coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $10.20.

Palisade Bio Trading Up 5.0%

Shares of NASDAQ:PALI opened at $1.89 on Thursday. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.85. The company’s 50 day moving average is $1.95 and its 200 day moving average is $1.91. The company has a market cap of $328.07 million, a PE ratio of -1.87 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Equities research analysts predict that Palisade Bio will post -0.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Palisade Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new position in shares of Palisade Bio during the 4th quarter valued at approximately $28,318,000. Commodore Capital LP purchased a new stake in Palisade Bio during the fourth quarter worth $26,896,000. Janus Henderson Group PLC boosted its holdings in Palisade Bio by 1.4% during the first quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after buying an additional 149,118 shares in the last quarter. Octagon Capital Advisors LP grew its position in Palisade Bio by 7.4% during the first quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock valued at $17,984,000 after buying an additional 708,419 shares during the period. Finally, RA Capital Management L.P. purchased a new position in Palisade Bio in the fourth quarter valued at $16,742,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.